Beyond the Scale: A Smarter, Safer Approach to GLP-1 Therapy
Why the most effective GLP-1 protocols are about far more than the medication
Nikki Guzzo, PA-C & Brandon Guzzo
Aspire Functional Aesthetics & Wellness
June 2025
The Conversation is Changing
Our Philosophy:
A medication placed into a metabolic vacuum produces incomplete results. GLP-1 therapy works best when the full picture — thyroid, hormones, inflammation, body composition, mitochondrial health, genetics — is understood first."
— Nikki Guzzo, PA-C
What These Medications Are Actually Doing
The 2026 Study That Changed Our Protocol for Women
Tirzepatide Only
-14.0%
total body weight lost
18% reached ≥20% TBWL
Tirzepatide + HRT
-19.2%
total body weight lost
45% reached ≥20% TBWL
Statistical Result
35% more weight lost
Δ −5.2% (95% CI: 1.90–8.54)
p = 0.0023
Additional benefits: ↓diastolic BP, ↓triglycerides, ↓AST in HRT group
The Body Composition Problem Nobody Talks About
Semaglutide vs Tirzepatide Lean Mass Gap:
~40–45% lean fraction (semaglutide) vs ~25–26% lean fraction (tirzepatide) — a ~15–20 percentage-point difference that constitutes one of the strongest arguments for preferring tirzepatide when clinically appropriate. On either agent, a muscle-protection protocol is not optional.
Semaglutide Only
~40–45%
of weight lost = lean mass
STEP 1 / SUSTAIN 8 DXA (Neeland 2024)
~1 lb muscle per 2.5 lbs lost. For 30 lbs total loss: up to 12 lbs could be muscle.
Tirzepatide Only
~25–26%
of weight lost = lean mass
SURMOUNT-1 DXA (Look 2025)
Better than semaglutide, but still ~1 lb muscle per 4 lbs lost without a protocol.
+ Protein ≥1.6g/kg +
Resistance 3–4×/wk
~11%
of weight lost = lean mass (89% fat)
SURMOUNT-1 protein/exercise subgroup
Protein + mechanical loading determines what tissue is lost — entirely within the patient's control.
+ HRT + Protein + Training.
(even postmenopausal)
Best
body composition outcome
Estrogen: activates ERα/ERβ in muscle; amplifies hypertrophy from training. HRT reduces bone loss 50–80%; WHI: 34% ↓hip fractures.
GIP (Tirzepatide): receptors on osteoblasts may confer additional bone-forming benefit.
The Aspire Protocol: Precision Before Prescribing
"We don't believe in starting any patient on a GLP-1 medication without first understanding their full metabolic picture."
— Brandon Guzzo, Aspire Functional Aesthetics & Wellness
1
Comprehensive Lab Panel — Metabolic, Hormonal & Inflammatory Baseline
Full-spectrum blood panel: thyroid (TSH, Free T3, Free T4, Reverse T3, TPO/TgAb antibodies); sex hormones (estradiol, progesterone, testosterone, SHBG, DHEA-S, LH, FSH); adrenal markers; insulin resistance (fasting insulin, HOMA-IR, HbA1c); advanced lipid panel; inflammatory markers (hsCRP, homocysteine, fibrinogen); liver/kidney function; CBC; nutrient status (vitamin D, B12, folate, magnesium, ferritin, zinc); IGF-1, leptin, adiponectin. This is not a standard metabolic panel — it is a comprehensive metabolic investigation.
2
Thyroid Screening — Non-Negotiable for Every Female Patient
GLP-1 medications cannot correct impaired T4→T3 conversion or low thyroid signaling. Women who struggle most on GLP-1 protocols frequently have undertreated or unrecognized hypothyroidism. Hypothyroid patients with constipation are at meaningful GI motility risk. Per Dr. Amie Hornaman (The Thyroid Fix): optimized T3 + GLP-1 therapy consistently produces superior fat loss outcomes vs either intervention alone. We screen every female patient before initiating therapy.
3
Hormonal Optimization — Peri- and Post-Menopausal Assessment
In light of Castaneda et al. (2026), every postmenopausal woman is assessed for HRT candidacy. Full hormonal evaluation, contraindication review, individualized benefit/risk discussion. We re-check every 12 weeks after HRT initiation — sub-therapeutic estrogen = sub-therapeutic metabolic benefit. The most underutilized clinical lever in functional medicine for women on GLP-1 therapy.
4
Monthly Biometric Testing — Tracking What Actually Matters
Advanced body composition analysis every month. We track skeletal muscle mass (lbs and %), body fat %, visceral fat level, bone density markers, and cellular hydration (phase angle). Phase angle is one of the most sensitive early indicators of lean tissue health without a DXA scan. We do not manage GLP-1 therapy by scale weight alone — a patient can show 12 lbs lost while simultaneously losing muscle at an alarming rate. We catch these patterns early and intervene.
5
PNOĒ Metabolic Testing — Quarterly for Body Composition & Human Optimization Programs
Every patient in our Lose Body Fat & Gain Lean Muscle program or Human Optimization Program receives a PNOĒ breath analysis every quarter. Provides: VO₂max (cardiovascular fitness & longevity marker), RMR and MBR, fat vs carbohydrate utilization ratios, mitochondrial health indicators, aerobic/anaerobic threshold. GLP-1 medications affect metabolic rate and substrate utilization in ways that vary significantly between individuals. Quarterly PNOĒ + bloodwork allows data-driven protocol adjustments rather than assumptions.
6
Microdosing Philosophy — The Aspire Standard
The majority of GLP-1 side effects are not caused by the medication — they are caused by dose escalation that happens too quickly. Standard pharmaceutical escalation schedules are designed for populations, not individuals. We begin at the lowest viable dose, hold until body composition data, energy, appetite response, and labs confirm readiness, and advance slowly. This is not optional caution — it is an ethical obligation. A patient who stops therapy due to debilitating nausea has not been served by aggressive titration.
7
Genetics, Methylation & Gut Microbiome Testing
For comprehensive human optimization patients: genetic testing covering methylation (MTHFR, COMT), detoxification capacity, nutrient metabolism variants, and hormonal processing genes — explaining why identical protocols produce different results between patients. Paired with gut microbiome analysis: a disrupted microbiome can blunt GLP-1 receptor sensitivity, impair signaling molecule synthesis, and sustain the inflammation these medications target. Baseline microbiome testing allows targeted interventions to maximize GLP-1 response from day one.
The Aspire Protocol: Precision Before Prescribing
The Aspire Commitment:
We do not consider GLP-1 therapy successful if a patient loses 20 pounds but arrives at their goal with less muscle, weaker bones, nutrient deficiencies, and no understanding of how to maintain results. Success means a stronger, healthier body — measurably confirmed in our biometric and metabolic data every single month.
Minimum Protection Protocol for Every Patient
For Postmenopausal Women — Additional Protocol
For Our Patients: What to Expect & What to Ask
If you are considering GLP-1 therapy, here are the questions you should feel empowered to ask — whether you're seeing us or any other provider:
Day-to-Day Best Practices on Therapy:
Questions to Ask Your Provider:
The Most Effective and Responsible Way Forward
Comprehensive testing → Precision dosing → Monthly biometric tracking → Quarterly metabolic & lab reassessment → Genetics + microbiome → Muscle & bone protection → Hormonal optimization
This is the Aspire GLP-1 Protocol — the most thorough, data-driven, and responsible approach we know how to build.
Clinical References
This article is for educational purposes only. Not individualized medical advice. Consult a qualified HCP before initiating any medication. Observational study findings (Castaneda 2026) do not establish causality — prospective RCTs are ongoing.

